Aspire Biopharma Holdings Inc
ASBP
Company Profile
Business description
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tract.
Contact
194 Candelaro Drive
Suite 223
HumacaoPR00791
USAT: +1 415 592-7399
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,126.90 | 73.70 | 0.92% |
| CAC 40 | 7,849.30 | 58.59 | 0.75% |
| DAX 40 | 22,363.06 | 199.57 | 0.90% |
| Dow JONES (US) | 42,001.76 | 417.86 | 1.00% |
| FTSE 100 | 8,655.03 | 72.22 | 0.84% |
| HKSE | 23,336.51 | 216.93 | 0.94% |
| NASDAQ | 17,299.29 | 23.70 | -0.14% |
| Nikkei 225 | 35,624.48 | 6.92 | 0.02% |
| NZX 50 Index | 12,312.60 | 42.60 | 0.35% |
| S&P 500 | 5,611.85 | 30.91 | 0.55% |
| S&P/ASX 200 | 7,925.20 | 81.80 | 1.04% |
| SSE Composite Index | 3,348.44 | 12.69 | 0.38% |